---
title: "Is the reported $400 billion AstraZeneca-Bristol Myers Squibb megamerger a slam dunk or a disaster waiting to happen?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295875984.md"
description: "There's a good reason why AstraZeneca tanked when merger rumors hit the Street."
datetime: "2026-08-14T03:10:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295875984.md)
  - [en](https://longbridge.com/en/news/295875984.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295875984.md)
generator: "portal-rs"
---

# Is the reported $400 billion AstraZeneca-Bristol Myers Squibb megamerger a slam dunk or a disaster waiting to happen?

There's a good reason why AstraZeneca tanked when merger rumors hit the Street.

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [AstraZeneca publishes transcript of ERS 2026 investor call and webcast](https://longbridge.com/en/news/298346504.md)
- [Bristol Myers Swoons on Test Results](https://longbridge.com/en/news/298335284.md)
- [BMS reports positive data from Phase II QUINTESSENTIAL study for r/r MM](https://longbridge.com/en/news/298442546.md)
- [AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears](https://longbridge.com/en/news/298828016.md)
- [Health Rounds: AstraZeneca drug reduces lung disease flare-ups in late-stage trials](https://longbridge.com/en/news/298355260.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**